Welcome to the REVLIMID REMS® program
Important information about REVLIMID and the REVLIMID Risk Evaluation
and Mitigation Strategy (REMS) program
-
REVLIMID is contraindicated in pregnant females and females capable of becoming pregnant. Females of reproductive potential may be treated with REVLIMID provided adequate precautions are taken to avoid pregnancy
-
To avoid embryo-fetal exposure, REVLIMID is only available under a restricted distribution program called "REVLIMID REMS®"
-
Only prescribers and pharmacies certified by the REVLIMID REMS® program can prescribe and dispense REVLIMID to patients who are enrolled and meet all the conditions of the REVLIMID REMS® program
The goals of the REVLIMID risk evaluation and mitigation strategy are as follows:
-
To prevent the risk of embryo-fetal exposure to REVLIMID
-
To inform prescribers, patients, and pharmacists on the serious risks and safe-use conditions for REVLIMID
For additional information about the REVLIMID REMS® program, please contact the Celgene Customer Care Center at 1-888-423-5436
REVLIMID® and REVLIMID REMS® are registered trademarks of Celgene Corporation.
© 2013-2019. Celgene Corporation, www.celgene.com.
This website is intended for residents of the United States only.
